Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 21;22(1):118.
doi: 10.1186/s12874-022-01569-x.

Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs

Affiliations

Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs

Yu Wang et al. BMC Med Res Methodol. .

Abstract

Background: Pediatric population presents several barriers for clinical trial design and analysis, including ethical constraints on the sample size and slow accrual rate. Bayesian adaptive design methods could be considered to address these challenges in pediatric clinical trials.

Methods: We developed an innovative Bayesian adaptive design method and demonstrated the approach as a re-design of a published phase III pediatric trial. The innovative design used early success criteria based on skeptical prior and early futility criteria based on enthusiastic prior extrapolated from a historical adult trial, and the early and late stopping boundaries were calibrated to ensure a one-sided type I error of 2.5%. We also constructed several alternative designs which incorporated only one type of prior belief and the same stopping boundaries. To identify a preferred design, we compared operating characteristics including power, expected trial size and trial duration for all the candidate adaptive designs via simulation when performing an increasing number of equally spaced interim analyses.

Results: When performing an increasing number of equally spaced interim analyses, the innovative Bayesian adaptive trial design incorporating both skeptical and enthusiastic priors at both interim and final analyses outperforms alternative designs which only consider one type of prior belief, because it allows more reduction in sample size and trial duration while still offering good trial design properties including controlled type I error rate and sufficient power.

Conclusions: Designing a Bayesian adaptive pediatric trial with both skeptical and enthusiastic priors can be an efficient and robust approach for early trial stopping, thus potentially saving time and money for trial conduction.

Keywords: Bayesian adaptive design; Interim analysis; Pediatric clinical trials; Prior belief.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Distribution of Prior Beliefs
Fig. 2
Fig. 2
Type I Error (under H0) and Power (under H1) for Bayesian Adaptive Designs. a and (b) are Bayesian adaptive design 1 that only allow early stopping for success based on skeptical prior; (c) and (d) are Bayesian adaptive design 2 that only allow early stopping for futility based on enthusiastic prior; (e) and (f) are Bayesian adaptive design 3 that allow early stopping for success based on skeptical prior, or early stopping for futility based on enthusiastic prior; (g) and (h) are Bayesian adaptive design 4 that allow early stopping for either success or futility both based on non-informative prior
Fig. 3
Fig. 3
Futility Rate for Bayesian Adaptive Designs under Null (H0) and Alternative (H1) Scenarios. a and (b) are Bayesian adaptive design 1 that only allow early stopping for success based on skeptical prior; (c) and (d) are Bayesian adaptive design 2 that only allow early stopping for futility based on enthusiastic prior; (e) and (f) are Bayesian adaptive design 3 that allow early stopping for success based on skeptical prior, or early stopping for futility based on enthusiastic prior; (g) and (h) are Bayesian adaptive design 4 that allow early stopping for either success or futility both based on non-informative prior
Fig. 4
Fig. 4
Mean Sample Size and Trial Duration for Bayesian Adaptive Designs under Null (H0) and Alternative (H1) Scenarios. a and (b) are Bayesian adaptive design 1 that only allow early stopping for success based on skeptical prior; (c) and (d) are Bayesian adaptive design 2 that only allow early stopping for futility based on enthusiastic prior; (e) and (f) are Bayesian adaptive design 3 that allow early stopping for success based on skeptical prior, or early stopping for futility based on enthusiastic prior; (g) and (h) are Bayesian adaptive design 4that allow early stopping for either success or futility both based on non-informative prior
Fig. 5
Fig. 5
Mean Sample Size and Trial Duration for Bayesian Adaptive Designs under the Harmful Scenario. a and (b) are Bayesian adaptive design 1 that only allow early stopping for success based on skeptical prior; (c) and (d) are Bayesian adaptive design 2 that only allow early stopping for futility based on enthusiastic prior; (e) and (f) are Bayesian adaptive design 3 that allow early stopping for success based on skeptical prior, or early stopping for futility based on enthusiastic prior; (g) and (h) are Bayesian adaptive design 4 that allow early stopping for either success or futility both based on non-informative prior
Fig. 6
Fig. 6
Bayesian Adaptive Design Property the Preferred Design Demonstrating Early Success, Early Futility, and Full Accrual Results
Fig. 7
Fig. 7
Bayesian Adaptive Design Property for the Preferred Design Demonstrating Success, Futility, and Inconclusive Results

Similar articles

Cited by

References

    1. Gamalo-Siebers M, et al. Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation. Pharm Stat. 2017;16(4):232–249. doi: 10.1002/pst.1807. - DOI - PubMed
    1. Allen HC, et al. Off-Label Medication use in Children, More Common than We Think: A Systematic Review of the Literature. J Okla State Med Assoc. 2018;111(8):776–783. - PMC - PubMed
    1. Neel DV, Shulman DS, Dubois SG. Timing of first-in-child trials of FDA-approved oncology drugs. Eur J Cancer. 2019;112:49–56. doi: 10.1016/j.ejca.2019.02.011. - DOI - PMC - PubMed
    1. Joseph PD, Craig JC, Caldwell PHY. Clinical trials in children. Br J Clin Pharmacol. 2015;79(3):357–369. doi: 10.1111/bcp.12305. - DOI - PMC - PubMed
    1. EMA. ICH E11(R1) guideline on clinical investigation of medicinal products in the pediatric population. 2017 [Cited 2021 April 21]; Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e11r1-gu...

LinkOut - more resources